Canada's Bausch Health Q4 revenue rises 9%, reports net loss

Bausch Health Companies

18/02/2026 21:27

Overview

Pharmaceutical company reported Q4 revenue up 9% yr/yr

Adjusted EBITDA for Q4 rose 13% yr/yr

Company completed acquisition of Shibo's full-service aesthetics business in China

Outlook

Bausch Health forecasts 2026 revenue between $10.625 bln and $10.875 bln

Company expects 2026 adjusted EBITDA between $3.875 bln and $4.000 bln

Bausch Health anticipates 2026 revenue growth of 2% to 5%

Result Drivers

SALIX SEGMENT - Growth in the Salix segment, driven by Xifaxan, contributed to revenue increase

ACQUISITION IN CHINA - Acquisition of Shibo's aesthetics business in China expands market reach

DEBT REFINANCING - Executed $1.7 bln debt exchange offer, extending maturities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$2.80 bln
Q4 EPS
-$0.30
Q4 Net Income
-$112 mln
Q4 Adjusted EBITDA
$1.05 bln
Q4 Operating Income
$474 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Bausch Health Companies Inc is $8.00, about 33.6% above its February 17 closing price of $5.99

The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 2 three months ago

Press Release: ID:nPn4lsGNTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)